Mirum's Rare Disease Bet Faces Its Most Important Proof Point

Mirum Pharmaceuticals reports second quarter 2026 earnings after market close on August 5, 2026, with analysts expecting a loss of $0.77 per share on revenue of $170 million. The rare disease specialist faces a critical test as investors assess whether its flagship therapy LIVMARLI can sustain commercial momentum in Alagille syndrome and progressive familial intrahepatic cholestasis indications amid a challenging year-over-year comparison. With the stock trading at $104.33 and Wall Street maintaining a Strong Buy consensus, the report will determine whether recent technical weakness represents a buying opportunity or signals deeper concerns about the growth trajectory.

Part 1: Earnings Preview

Mirum Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare liver diseases, with its lead product LIVMARLI approved for treating cholestatic pruritus in Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). The company has transitioned from development to commercialization, making revenue growth and market penetration the primary drivers of its investment thesis.

For the second quarter ending June 2026, analysts expect Mirum to report a loss of $0.77 per share on revenue of $170 million. The most recently reported quarter (Q1 2026) showed a loss of $0.39 per share. Compared to the same quarter last year when the company reported a loss of $0.12 per share, the consensus estimate represents a significant deterioration of 541.67% year-over-year, reflecting increased investment in commercial infrastructure and global expansion efforts.

Three key themes define this earnings story:

LIVMARLI Commercial Execution: Investors will scrutinize net product revenue growth and prescription trends across both ALGS and PFIC patient populations. Market penetration rates, patient starts, and persistence data will signal whether the therapy is achieving sustainable adoption or facing reimbursement headwinds. Geographic expansion progress, particularly in international markets where regulatory approvals have been secured, remains critical to the long-term revenue trajectory.

Operating Leverage and Path to Profitability: With consensus estimates projecting a return to profitability in fiscal 2027 (estimated EPS of $0.13), management's commentary on operating expense discipline and gross margin trends will be crucial. Investors want visibility into when the commercial infrastructure investments will translate into positive cash flow, and whether the current burn rate is sustainable given the balance sheet position.

Pipeline Progress and Label Expansion: Beyond the base business, any updates on clinical trials for new indications, regulatory milestones, or potential label expansions could provide upside catalysts. The competitive landscape in rare liver disease therapeutics is evolving, making Mirum's ability to differentiate LIVMARLI and defend its market position increasingly important.

Leading analysts maintain a constructive view heading into the report, with the average price target of $145.80 implying 40% upside from current levels. The analyst community emphasizes that while near-term losses are expected as the company scales its commercial operations, the long-term opportunity in underserved rare disease populations justifies the investment phase. Key metrics to watch include patient enrollment velocity, payer coverage decisions, and any guidance updates for the full-year 2026 outlook.

Part 2: Historical Earnings Performance

Mirum has demonstrated a mixed but generally positive track record of earnings surprises over the past four quarters. The company beat estimates in three of the last four reports, with particularly strong outperformance in Q2 2025 (+150.00% surprise) and Q1 2025 (+61.29% surprise). However, Q3 2025 delivered a significant miss with a -650.00% surprise, reporting a loss of $0.11 against expectations of a $0.02 profit.

The most recent quarter (Q1 2026) showed a return to form with a modest beat, reporting $-0.39 versus the $-0.40 estimate for a +2.50% surprise. This suggests management has recalibrated expectations following the Q3 disappointment. The pattern reveals a company in transition—capable of exceeding lowered bars but still facing execution challenges that can produce volatile results quarter to quarter.

The year-over-year comparison is particularly striking: Q2 2025 delivered $-0.12 per share, while the current quarter's estimate of $-0.77 represents a substantial increase in losses. This reflects the company's aggressive investment in commercial expansion, which analysts view as necessary for long-term growth but creates near-term pressure on profitability metrics.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Mirum typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

Historical price action around Mirum earnings shows significant volatility, with an average absolute Day +1 move of 7.24% and an average range of 10.31%. The most dramatic reactions occurred in February 2026, when the stock fell 15.13% the day after earnings, and August 2025, when it surged 12.04% following the report. The May 2026 earnings (most recent) produced a 4.04% gain on Day 0 but reversed to a 6.50% decline on Day +1, suggesting initial optimism gave way to concerns upon closer examination of the results.

The pattern reveals a stock prone to sharp post-earnings swings in both directions, with Day +1 moves consistently larger than Day 0 anticipation. Investors should prepare for potential double-digit percentage moves, particularly given the company's transition phase and the market's sensitivity to commercial execution metrics. The historical average suggests moves well above typical market volatility, reflecting the binary nature of rare disease commercial stories.

Part 2.2: Options Market Expected Move

The options market is pricing an 8.63% expected move for the August 21 expiration, slightly above the historical Day 0 average of 4.89% but below the 7.24% average Day +1 move. This suggests options traders are anticipating meaningful volatility but not the extreme swings seen in some prior quarters, positioning for a reaction in line with recent history rather than the outlier moves of early 2026.

Part 3: What Analysts Are Saying

Analysts maintain a strongly bullish stance on Mirum, with an average rating of 4.80 out of 5.00, firmly in Strong Buy territory. The consensus includes 13 Strong Buy ratings, 1 Moderate Buy, and 1 Hold, with zero sell recommendations. This represents an unchanged sentiment trend over the past month, indicating stable conviction despite recent stock price weakness.

The average price target of $145.80 implies 39.7% upside from the current price of $104.33, with a range spanning from a low of $125.00 to a high of $185.00. Even the most conservative target suggests 19.8% upside, while the bull case envisions 77.4% appreciation. This wide range reflects differing views on the pace of LIVMARLI adoption and the timeline to profitability, but the clustering of Strong Buy ratings indicates broad agreement that the risk-reward profile favors long-term holders.

The unchanged sentiment despite the stock's recent decline below multiple moving averages suggests analysts view current levels as attractive entry points rather than a signal to downgrade. The consensus appears to be that near-term losses are priced in and that the focus should remain on commercial execution metrics and the path to the projected 2027 profitability inflection point.

Part 4: Technical Picture

The Barchart Technical Opinion currently shows a 56% Buy signal, representing a significant deterioration from 88% Buy one week ago and 100% Buy one month ago. This rapid weakening reflects the stock's recent decline from higher levels, with MIRM now trading at $104.33, below its 5-day ($107.01), 10-day ($110.33), 20-day ($115.63), and 50-day ($109.59) moving averages. The stock remains above its longer-term 100-day ($102.99) and 200-day ($92.80) moving averages, suggesting the broader uptrend remains intact despite near-term weakness.

Timeframe Analysis:

• Short-term (50% Buy): Neutral-to-positive signal indicates near-term momentum has stalled, with the stock consolidating after recent declines
• Medium-term (50% Buy): Moderate buy signal suggests the intermediate trend remains constructive despite the pullback from recent highs
• Long-term (100% Buy): Strong buy signal confirms the longer-term uptrend remains firmly in place, supported by the stock's position well above its 200-day moving average

Trend Characteristics: The Average strength combined with the Weakest direction indicates a trend environment that has lost momentum heading into earnings, with the stock vulnerable to further downside if results disappoint but positioned for a sharp reversal if the company delivers positive surprises.

Key technical levels to watch include support at the 100-day moving average of $102.99, which sits just below the current price and represents the line between a healthy pullback and a more serious breakdown. Resistance has formed at the 20-day moving average of $115.63, which would need to be reclaimed to signal a return to the prior uptrend. The stock's position in the lower end of its recent range, combined with weakening short-term momentum but strong long-term trend characteristics, creates a mixed technical setup heading into earnings. The configuration suggests the report could act as a catalyst for either a bounce back toward $115+ if results exceed expectations, or a test of the $100-$103 support zone if the company disappoints. The 17-day window to August options expiration provides a defined risk period for traders positioning around the event.